Total US pharma industry M&A deals in Q4 2018 worth $11.95bn were announced, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 27.2% over the previous quarter and a drop of 22.6% when compared with the last four-quarter average of $15.43bn.
The United States held an 81.5% share of the global pharma industry M&A deal value that totalled $14.66bn in Q4 2018.
In terms of deal activity, the United States recorded 70 deals during Q4 2018, marking a rise of 6.1% over the previous quarter and a rise of 27.3% over the last four-quarter average.
US pharma industry M&A deals in Q4 2018: Top deals
The top five pharma industry M&A deals accounted for 90.4% of the overall value during Q4 2018.
The combined value of the top five pharma industry M&A deals stood at $10.8bn, against the overall value of $11.95bn recorded for the quarter. The top announced pharma industry M&A deal tracked by GlobalData in Q4 2018 was GlaxoSmithKline’s $5.1bn acquisition of TESARO.
The $1.2bn acquisition of Pacific Biosciences of California by Illumina and AMAG Pharmaceuticals and Magellan Merger Sub’s acquisition of Perosphere Pharmaceuticals for $433.2m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.